Patents by Inventor Marc Lemieux

Marc Lemieux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method, system and apparatus for dynamically monitoring and calibrating display tiles
    Patent number: 9059337
    Abstract: A method, system and apparatus for dynamically monitoring and calibrating display tiles are provided. The apparatus comprises: an array of light emitting devices; one or more light emitting devices paired with light emitting devices of the array; one or more sensors configured to detect an optical characteristic and/or an electrical characteristic of the one or more paired light emitting devices; and, circuitry configured to: drive the array; drive each of the one or more further light emitting devices under same conditions as light emitting devices of the array; temporarily drive each of the one or more paired light emitting devices under different conditions from the array; and, adjust driving of the array based on the optical characteristic and/or electrical characteristic of the one or more paired light emitting devices detected at sensor(s) when the one or more paired light emitting devices are driven under the different conditions.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: June 16, 2015
    Assignee: CHRISTIE DIGITAL SYSTEMS USA, INC.
    Inventors: James Robinson, Marc Lemieux
  • Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
    Patent number: 8980918
    Abstract: The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD2 at the CRTH2 receptor.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 17, 2015
    Assignee: Atopix Therapeutics Limited
    Inventors: Aimesther Betancourt, Marc Lemieux, Roch Thibert
  • Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid
    Publication number: 20140255340
    Abstract: The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD2 at the CRTH2 receptor.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 11, 2014
    Applicant: Atopix Therapeutics Limited
    Inventors: Betancourt Aimesther, Marc Lemieux, Roch Thibert
  • Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
    Patent number: 8703956
    Abstract: The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD2 at the CRTH2 receptor.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: April 22, 2014
    Assignee: Atopix Therapeutics Limited
    Inventors: Aimesther Betancourt, Marc Lemieux, Roch Thibert
  • Derivatives of 6,7-dihydro-5-imidazo[1,2-]imidazole-3-carboxylic acid amides
    Patent number: 8575360
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: November 5, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rene Marc Lemieux, Steven Richard Brunette, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Bryan McKibben, Craig Andrew Miller, Antonio J. M. Barbosa
  • Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides
    Patent number: 8552205
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-?]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: October 8, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Antonio Jose del Moral Barbosa, Jr., Joerg Martin Bentzien, Steven Richard Brunette, Zhidong Chen, Derek Cogan, Donghong A. Gao, Alexander Heim-Riether, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Rene Marc Lemieux, Weimin Liu, Bryan McKibben, Craig Andrew Miller, Neil Moss, Matt Aaron Tschantz, Zhaoming Xiong, Hui Yu, Yang Yu
  • Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid
    Publication number: 20120282223
    Abstract: The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD2 at the CRTH2 receptor.
    Type: Application
    Filed: March 7, 2012
    Publication date: November 8, 2012
    Inventors: Aimesther BETANCOURT, Marc LEMIEUX, Roch THIBERT
  • DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
    Publication number: 20120252817
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Application
    Filed: May 26, 2010
    Publication date: October 4, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rene Marc Lemieux, Steven Richard Brunette, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Bryan McKibben, Craig Andrew Miller, Antonio J. M. Barbosa
  • DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
    Publication number: 20110224188
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-?]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Application
    Filed: November 20, 2008
    Publication date: September 15, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Antonio Jose del Moral Barbosa, Joerg Martin Benzien, Steven Richard Brunette, Zhidong Chen, Derek Cogan, Donghong A. Gao, Alexander Heim-Riether, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Rene Marc Lemieux, Weimin Liu, Bryan Mckibben, Craig Andrew Miller, Neil Moss, Matt Aaron Tschantz, Zhaoming Xiong, Hui Yu, Yang Yu
  • Pyrimidine derivatives useful as inhibitors of PKC-theta
    Patent number: 7601714
    Abstract: Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: July 6, 2005
    Date of Patent: October 13, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Antonio J. M. Barbosa, Jr., Steven Richard Brunette, Eugene Richard Hickey, Jin Mi Kim, Michael David Lawlor, René Marc Lemieux, Bryan McKibben, Matt Aaron Tschantz, Hui Yu
  • Derivatives of [6,7-dihydro-5-imidazo[1,2-?]imidazole-3-sulfonylamino]-propionamide
    Patent number: 7589115
    Abstract: Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: October 15, 2007
    Date of Patent: September 15, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence Alfred Kelly, Jin Mi Kim, René Marc Lemieux
  • Substituted benzylimidazoles useful for the treatment of inflammatory diseases
    Patent number: 7572921
    Abstract: The invention comprises a class of derivatives of substituted benzylimidazoles of the formula (I) and methods for making the same. These compounds are useful for the treatment of inflammatory conditions.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: August 11, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jin Mi Kim, Rene' Marc Lemieux, Bryan McKibben, Matt Aaron Tschantz, Hui Yu
  • Derivatives of 6,7-dihydro-5h -imidazo[1,2-a] imidazole-3-sulfonic acid
    Patent number: 7517897
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: April 14, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Magnus Carl Arne Eriksson, Rene Marc Lemieux
  • Pyridine derivatives useful as inhibitors of PKC-theta
    Patent number: 7468382
    Abstract: Disclosed are novel compounds of formula (I): wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: December 23, 2008
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steven Richard Brunette, Jin Mi Kim, Rene′ Marc Lemieux, Matt Aaron Tschantz
  • Derivatives of [6,7-dihydro-5-imidazo[1,2-]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
    Patent number: 7462637
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: December 9, 2008
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence A. Kelly, Jin Mi Kim, René Marc Lemieux, Matt Aaron Tschantz
  • PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA
    Publication number: 20080287410
    Abstract: Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: July 11, 2008
    Publication date: November 20, 2008
    Inventors: Antonio J.M. BARBOSA, Steven Richard BRUNETTE, Eugene Richard HICKEY, Jin Mi KIM, Michael David LAWLOR, Rene Marc LEMIEUX, Bryan MCKIBBEN, Matt Aaron TSCHANTZ, Hui YU
  • Derivatives of [6,7-dihydro-5H-imidazol[1,2-a]imidazole-3-sulfonylamino]-propionamide
    Patent number: 7345074
    Abstract: Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: March 18, 2008
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence Alfred Kelly, Jin Mi Kim, René Marc Lemieux
  • Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
    Patent number: 7304067
    Abstract: Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: December 4, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence Alfred Kelly, Jin Mi Kim, René Marc Lemieux
  • Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
    Patent number: 6852748
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-?]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: February 8, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence Alfred Kelly, Jin Mi Kim, René Marc Lemieux, Matt Aaron Tschantz
  • Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
    Patent number: 6844360
    Abstract: Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: January 18, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence Alfred Kelly, Jin Mi Kim, René Marc Lemieux